[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"overweight-and-obesity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:overweight-and-obesity":31},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,94,0,25,[9,45,75,96,120,151,179,203,225,248,272,301,328,357,378,405,432,463,489,513,539,562,577,606,632],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100053559","cardiometabolic-effects-of-the-recommended-daily-pecan-intake-dose-100053559",false,"NCT07696403","Cardiometabolic Effects of the Recommended Daily Pecan Intake Dose","Cardiometabolic Effects of the Recommended Daily Pecan Intake Dose: A 12-Week Randomized Controlled Trial","Inclusion Criteria:\n\n* 25-75 year-old men and women at increased risk for cardiovascular disease. Increased risk for cardiovascular disease will be defined by either elevated cholesterol profiles -or- overweight\u002Fobesity.\n* Elevated cholesterol profiles will be defined as:\n* \"Borderline High\" and\u002For \"at risk\" in two or more of the following variables (total cholesterol: 180-239 mg\u002FdL, LDL cholesterol 110-159 mg\u002FdL, triglycerides 130-199 mg\u002FdL) --or-- \"High\" in total cholesterol (240 mg\u002FdL and higher), LDL (160 mg\u002FdL or higher), or triglycerides (between 200-350 mg\u002FdL).\n* Overweight\u002Fobesity will be defined by body mass index (overweight \\> 28 kg\u002Fm2 or obesity 30 kg\u002Fm2 or greater).\n\nExclusion Criteria:\n\n* Probable familial hypercholesterolemia, defined by: total cholesterol greater than 290 mg\u002FdL or LDL levels greater than 190 mg\u002FdL plus a family history of myocardial infarction (MI) before 50 years of age in a 2nd-degree relative or below age 60 in a 1st-degree relative.\n* Women on hormone replacement therapy less than 2 years.\n* Women who are pregnant or nursing\n* Individuals who regularly exercise more than 3h\u002Fw\n* Weight gain or loss of more than 5% body weight in the past 3 months\n* Plans to begin a weight loss\u002Fexercise regimen during the trial\n* History of medical or surgical events that could affect digestion or swallowing\n* Gastrointestinal surgeries, conditions, or disorders\n* Any chronic diseases (including moderate to severe asthma, chronic lung disease, and kidney disease)\n* Metabolic disease\n* Atherosclerosis\n* Previous MI or stroke\n* Cancer\n* Fasting blood glucose levels greater than 126 mg\u002FdL\n* Blood pressure greater than 180\u002F120 mmHg\n* Medication use affecting digestion, absorption, or metabolism (e.g. thyroid meds), lipid-lowering medications, medications for diabetes, steroid\u002Fhormone therapies, or current antibiotic cycles\n* Medically prescribed or special diets\n* Food allergies (specific to the foods in the study, including tree nuts, dairy, gluten, palm oil, and coconut oil)\n* Fish oil supplements\n* Individuals who regularly consume nuts and\u002For nut butter (defined as consumption of \\>2 servings (\\~56g) of tree nuts, nuts, or nut butter (e.g., peanut butter, almond butter) per week\n* Excessive alcohol use (greater than 3 drinks\u002Fday for men; greater than 2 drinks\u002Fday for women)\n* Tobacco or nicotine use\n* Underweight BMI (\\\u003C18.5 kg\u002Fm²)",true,"ALL","25 Years","75 Years",{"count":22,"type":23},90,"ESTIMATED","INTERVENTIONAL",[26],"NA","Cardiovascular disease risk factors, including higher BMIs and poor cholesterol profiles, are on the rise and contribute to the United States' growing disease burden. The bioactive compounds contained in tree nuts have been shown to beneficially affect cardiometabolic health outcomes. Pecans contain more total phenols, sterols, and flavonoids than any other tree nut. They also are a rich source of polyunsaturated fatty acids (PUFAs), fiber, vitamin A, vitamin E, folic acid, calcium, magnesium, phosphorus, potassium, and zinc. These bioactive components in pecans are likely the reason for the previously documented improvements in cardiometabolic health. This study aims to examine the impact of a low dose of pecans on changes in fasting and postprandial lipid metabolism\u002Fblood lipids and markers of chronic disease risk.\n\nThe specific aims of this study are to:\n\n* Examine the effect of pecan consumption at a dose of 6% of total energy needs for 12 weeks on fasting and postprandial blood lipids.\n* Examine the effect of pecan consumption at a dose of 6% of total energy needs for 12 weeks on other markers of chronic disease risk.\n\nParticipants will be asked to:\n\n* Consume pecans daily for 12 weeks or maintain their current habitual diet.\n* Attend two short visits at 4 and 8 weeks for fasting blood draws, body measurements, and to collect their next 4 weeks' supply of study materials.\n* Attend two longer (5 h) testing visits, which include eating a standard breakfast meal and having their blood drawn periodically before and after breakfast.\n\nResearchers will compare the Pecan and Control groups to examine the physiologic effects of incorporating a low dose of pecans into one's diet.",[29,30,31],"Nutrition, Healthy","Dyslipidemia","Overweight and Obesity","NOT_YET_RECRUITING","2026-07-09",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":23},"2026-08",{"date":40,"type":23},"2029-07",{"name":42,"class":43},"University of Georgia","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":53,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":24,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":44},"100553857","time-restricted-eating-for-postpartum-weight-loss-100553857","NCT06491537","Time-restricted Eating for Postpartum Weight Loss","Use of Early Time-restricted Eating to Promote Weight Loss and Improve Cardiometabolic Health in Postpartum Women","Time4Mom","Inclusion Criteria:\n\n* 18 years of age or older\n* Experienced a healthy singleton pregnancy\n* 6-16 weeks postpartum at enrollment\n* Body mass index ≥25 at enrollment\n* Willing to consent\n\nExclusion Criteria:\n\n* Self-reported major health condition (such as renal disease, cancer, or Type 1 or Type 2 diabetes)\n* Current treatment for severe psychiatric disorder (such as schizophrenia)\n* Self-reported diagnosis of anorexia or bulimia\n* Current use of medication expected to significantly impact body weight\n* Current substance abuse\n* Participation in another dietary and\u002For weight management intervention postpartum\n* Performing overnight shiftwork \\>1x\u002Fweek\n* Regularly fasting ≥14 hr\u002Fday or completing twelve or more 24-hr fasts within the past year\n* Unable to understand and communicate in English","FEMALE","18 Years",{"count":56,"type":23},60,[26],"This study is being done to assess the feasibility and acceptability of a time-restricted eating intervention among postpartum women with overweight\u002Fobesity.",[60,31],"Postpartum Weight Retention",[62,63,64],"postpartum","weight management","time-restricted eating","RECRUITING","2026-06-24",{"date":68,"type":36},"2026-06-29",{"date":70,"type":36},"2025-05-22",{"date":72,"type":23},"2029-02-01",{"name":74,"class":43},"University of Alabama at Birmingham",{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":17,"sex":18,"minAge":54,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":44},"100487846","breathing--blood-pressure-100487846","NCT05632406","Breathing & Blood Pressure","Inclusion Criteria:\n\n• Body mass index values of ≤40 kg\u002Fm\\^2\n\nExclusion Criteria:\n\n* Not weight stable (\\\u003C5% change in body mass over the past six months)\n* Overt cardiovascular, neurological, renal, liver, and\u002For metabolic illness (e.g., diabetes mellitus)\n* Current, or history of uncontrolled, Stage 2 hypertension (blood pressure \\>140 \u002F 90 mmHg; anti-hypertensive medications are permitted)\n* Diagnosed obstructive sleep apnea\n* Previous bariatric surgery\n* Diagnosis or signs (e.g., values below the lower limit of normal) of overt airway disease(s)\n* Current or recent (regular use within the past 6 months) use of tobacco or nicotine products (e.g., cigarettes, vaping)\n* Per the POWERbreathe® company:\n* Patients who have undergone recent abdominal surgery and those with abdominal hernia.\n* Asthma patients who have a very low symptom perception and suffer from frequent, severe exacerbations or with an abnormally low perception of dyspnoea.\n* If a patient is suffering from a ruptured eardrum or any other condition of the ear.\n* Patients with marked elevated left ventricular end-diastolic volume and pressure.\n* Patients with worsening heart failure signs and symptoms after a respiratory\u002Finspiratory muscle training (IMT) session\n* If you are suffering from a cold, sinusitis, or respiratory tract infection, we advise that you do not use your POWERbreathe IMT device.\n* Individuals who are not yet adults (infants, children, teenagers)\n* Pregnant (self-reported and urine pregnancy test conducted), lactating (self-reported), or post-menopausal (self-reported) females\n* Prisoners","45 Years",{"count":83,"type":23},80,"OBSERVATIONAL","The purpose of this study is to determine the effect of obesity on cardiovascular responses during various breathing maneuvers.",[87,31],"Healthy",{"date":89,"type":36},"2026-06-26",{"date":91,"type":36},"2023-10-25",{"date":93,"type":23},"2027-06-30",{"name":95,"class":43},"Florida State University",{"id":97,"slug":98,"hasResults":12,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":12,"sex":53,"minAge":54,"maxAge":81,"enrollmentInfo":104,"targetDuration":4,"studyType":24,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100448849","intensive-glycemic-targets-in-overweight-and-obese-women-with-gestational-diabetes-100448849","NCT05124808","Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes","Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes Mellitus: A Multicenter Randomized Trial","iGDM","Inclusion Criteria:\n\n* Pregnant women between the ages of 18-45\n* Singleton gestation\n* Gestational age between 12 0\u002F7-32 6\u002F7 weeks' gestation with gestational diabetes diagnosed during this time frame using either a 50g 1-hr GCT ≥200 mg\u002FdL or two or more abnormal values on a 100g OGTT using the Carpenter-Coustan Criteria\n* Overweight or obese BMI at the first prenatal visit (BMI ≥25 kg\u002Fm2 or ≥23 kg\u002Fm2 in Asian Americans)\n\nExclusion Criteria:\n\n* Inability or unwillingness to provide informed consent\n* Inability to communicate with members of the study team, despite the presence of an interpreter\n* Planned delivery at a non-study affiliated hospital\n* Known renal disease with a baseline creatinine \\>1.5 mg\u002FdL\n* Significant fetal anomalies diagnosed prior to study enrollment (these will include anomalies such as gastroschisis, spina bifida, complex congenital heart disease, or serious karyotypic anomalies that may lead to early delivery or increased risk of neonatal death)\n* Oral or IV\u002FIM steroid use within 7 days of study enrollment",{"count":105,"type":23},828,[26],"This is a multicenter randomized clinical trial of 828 overweight and obese individuals with gestational diabetes designed to compare standard to intensive glycemic targets.",[109,110,31],"Gestational Diabetes","Pregnancy, High Risk","2026-06-22",{"date":66,"type":36},{"date":114,"type":36},"2022-03-01",{"date":116,"type":23},"2026-12-31",{"name":118,"class":43},"Indiana University",5,{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":130,"conditions":131,"keywords":132,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":44},"100641777","validity-and-reliability-of-mixed-reality-based-performance-tests-in-overweight-and-obese-adults-100641777","NCT07654439","Validity and Reliability of Mixed Reality-Based Performance Tests in Overweight and Obese Adults","Validity and Reliability of the Mixed Reality Adaptation of Performance Tests in Overweight and Obese Individuals","Inclusion Criteria:\n\n* Body Mass Index (BMI) ≥ 25 kg\u002Fm² (overweight or obesity),\n* Ability to ambulate independently,\n* Aged between 18 and 65 years,\n* Willingness to participate voluntarily in the study and provide written informed consent.\n\nExclusion Criteria:\n\n* Use of anti-obesity medication,\n* Pregnancy,\n* Latent autoimmune diabetes in adults (LADA),\n* Chronic kidney disease,\n* Active or severe infections,\n* Liver failure,\n* Recent major cardiovascular events,\n* Unstable angina,\n* Heart failure classified as New York Heart Association (NYHA) Class III-IV,\n* Respiratory failure, cardiac arrhythmias, neoplastic diseases, or neurological or musculoskeletal disorders that may limit the safe performance of the tests.","65 Years",{"count":129,"type":23},119,"This study aims to evaluate the validity and reliability of mixed reality (MR)-based adaptations of functional mobility and performance tests developed using the Meta Quest 3 platform by comparing their outcomes with conventional clinical assessments. Virtual and mixed reality technologies have gained increasing attention in clinical measurement due to their potential advantages, including assessment standardization, enhanced user interaction, and automated data collection.\n\nPrevious studies have demonstrated that virtual reality-based performance assessments can provide high reliability and show meaningful associations with traditional clinical measures across different populations. However, visual and vestibular stimuli, depth perception, and changes in movement strategies may cause performance in virtual environments to differ from performance in conventional settings. Therefore, the validity and reliability of each virtual or mixed reality adaptation should be established within the target population.\n\nOverweight and obese individuals exhibit biomechanical and physiological characteristics that may affect balance, gait mechanics, joint loading, and physical performance. Consequently, measurement properties established in other populations cannot be assumed to apply directly to overweight and obese individuals. In addition, factors related to head-mounted displays and motion-tracking systems may influence assessment outcomes.\n\nThe purpose of this study is to evaluate the concurrent validity and test-retest reliability of mixed reality-based performance tests developed using the Meta Quest 3 platform. Measurement error parameters will also be determined to assess the clinical applicability of these MR-based assessments.\n\nThe findings of this study are expected to contribute to the development of safe, standardized, digital, and potentially remote assessment approaches for evaluating functional performance in overweight and obese individuals. Furthermore, the results may strengthen the scientific evidence supporting the use of digital assessment technologies in clinical practice.",[31],[133,134,135,136,137,138,139,140,141],"Overweight","Obesity","Mixed Reality","6-Minute Walk Test","Timed Up and Go Test","Five-Repetition Sit-to-Stand Test","Functional Performance","Validity","Reliability","2026-06-12",{"date":144,"type":36},"2026-06-17",{"date":146,"type":36},"2026-06-10",{"date":148,"type":23},"2027-05-10",{"name":150,"class":43},"Selcuk University",{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":12,"sex":53,"minAge":54,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":24,"phases":160,"briefSummary":161,"conditions":162,"keywords":165,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":44},"100486871","healthy-for-two-home-visiting-h42-hv-health-coaching-for-pregnant-women-100486871","NCT05619705","Healthy for Two-Home Visiting (H42-HV): Health Coaching for Pregnant Women","Effectiveness of Health Coaching to Reduce Cardiometabolic Risk in Early Home Visiting Services","Inclusion Criteria:\n\n* Pregnant, ≤33 weeks gestation\n* Singleton pregnancy\n* Pre pregnancy BMI≥25.0 Kg\u002Fm\\^2 (calculated based on self-reported pre pregnancy height and weight)\n* Able to provide informed consent\n* English or Spanish speaking\n* Completion of screening and baseline data collection\n* Willing to participate in the intervention and data collection procedure (e.g., home weights)\n\nExclusion Criteria:\n\n* Type 1 diabetes or taking insulin prior to delivery\n* Pregnant with multiple fetuses\n* Unable to walk 1 block without pain or shortness of breath\n* Not cleared by the study's clinicians or home visiting program staff\n* Planning to relocate from area during next 1 year\n* Active substance abuse disorder (except marijuana)\n* Psychiatric or substance use related hospitalization in past 1 year\n* Active eating disorder",{"count":159,"type":23},360,[26],"The purpose of this study is to compare the effectiveness of H42-HV integrated into home visiting compared with usual home visiting services in reducing postpartum weight retention (difference between pre-pregnancy weight and weight at 6 months postpartum) among pregnant and postpartum participants. The overall goal is to improve long-term cardiometabolic health.",[60,163,31,164],"Pregnancy Weight Gain","Behavior, Health",[166,167,133,134,168,169],"Behavioral Intervention","Early Childhood Home Visiting","Postpartum","Pregnancy","2026-06-04",{"date":172,"type":36},"2026-06-08",{"date":174,"type":36},"2023-04-25",{"date":176,"type":23},"2026-12-15",{"name":178,"class":43},"Johns Hopkins University",{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":12,"sex":53,"minAge":54,"maxAge":81,"enrollmentInfo":186,"targetDuration":4,"studyType":24,"phases":188,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":44},"100463576","phase-2-weight-management-plus-lng-iusmegestrol-acetate-in-endometrial-atypical-hyperplasia-100463576","NCT05316493","Weight Management Plus LNG-IUS\u002FMegestrol Acetate in Endometrial Atypical Hyperplasia","Weight Management Plus Levonorgestrel Intrauterine System or Megestrol Acetate in Endometrial Atypical Hyperplasia: Multiple Single-arm, Prospective and Open-label Clinical Study","Inclusion Criteria:\n\n1.18 years≤age≤45years 2.BMI (body mass index) ≥24kg\u002Fm2 3.Consent informed and signed 4.Pathologically confirmed as endometrial atypical hyperplasia. Patients with endometrial specimens obtained by endometrial biopsy, diagnostic curettage or hysteroscopy and diagnosed histologically as endometrial atypical hyperplasia. If specimens are from other hospitals, they must be counseled or reconfirmed by the Department of Pathology of the Obstetrics and Gynecology Hospital of Fudan University.\n\n5.Have a strong desire to reproduce and ask for fertility preservation or those who insist on keeping the uterus despite no reproductive requirements.\n\n6.Have good compliance and follow-up conditions, and patients are willing to follow up in Obstetrics and Gynecology Hospital of Fudan University in time.\n\nExclusion Criteria:\n\n1. Combined with severe medical disease or liver or kidney dysfunction: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level elevates to 3 times or more of the upper limit of normal, kidney dysfunction (creatinine clearance \\\u003C 30 mL\u002Fmin)\n2. Patients are diagnosed with other malignant tumors of the reproductive system; patients with breast cancer or other hormone-dependent tumors that cannot be used with progesterone.\n3. Those who have received high doses of high potency progestin or oral contraceptives within the last 3 months (or those on maintenance medication).\n4. Those who require hysterectomy or other methods other than conservative treatment.\n5. Known or suspected pregnancy.\n6. Those who has contraindications to use progestin.\n7. Deep vein thrombosis, stroke, myocardial infarction.\n8. Severe joint lesions that prevent walking or movement.\n9. untreated or recurrent pelvic inflammatory disease (PID)\n10. an untreated or uncontrolled pelvic infection (vaginal, cervical, uterine);\n11. Cervical dysplasia\n12. Congenital or acquired uterine abnormalities, including uterine fibroid tumors or conditions that affect the shape of the uterus\n13. allergic to the LNG-IUS components\n14. uterine cavity is too large (average uterine diameter is over 7 cm) or have a history of LNG-IUS falling out.\n\nNotes: the last 6 criteria are only applied for patients with LNG-IUS.",{"count":187,"type":23},172,[189,190],"PHASE2","PHASE3","To investigate the efficacy of weight management plus levonorgestrel intrauterine system (LNG-IUS) or megestrol acetate (MA) in obese patients with endometrial atypical hyperplasia (EAH) asking for conservative therapy.",[193,194,31],"Atypical Endometrial Hyperplasia","Fertility Issues","2026-06-03",{"date":170,"type":36},{"date":198,"type":36},"2022-06-13",{"date":200,"type":23},"2027-02-28",{"name":202,"class":43},"Xiaojun Chen",{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":17,"sex":53,"minAge":54,"maxAge":81,"enrollmentInfo":210,"targetDuration":4,"studyType":24,"phases":212,"briefSummary":213,"conditions":214,"keywords":215,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":44},"100424331","pregnancy-exercise-mode-effect-on-childhood-obesity-100424331","NCT04805502","Pregnancy Exercise Mode Effect on Childhood Obesity","Effect of Exercise Modality During Pregnancy on Childhood Obesity Risk","Inclusion Criteria:\n\n* Age: 18 to 40 years old\n* BMI between ≥ 25\n* Pregnancy: Singleton; ≤ 16 weeks gestation\n* Clearance by Obstetric provider for exercise\n\nExclusion Criteria:\n\n* Age: ≤ 17.9 or ≥ 41 years of age\n* BMI \\\u003C25\n* Multi fetal pregnancy\n* Obstetric Provider does not provide clearance for exercise\n* Unable or Unwilling to provide consent\n* Inability to communicate with members of study team, despite use of interpreter\n* Medical Conditions (e,g. HIV\u002FAids, Cancer, Type 1 or 2 Diabetes, Untreated Hypertension, Thyroid Disorders)\n* Use of tobacco products, alcohol, recreational drugs, or medications (oral hypertensive, insulin)\n* Unable to provide phone or email contact",{"count":211,"type":23},300,[26],"The overall objective of this proposal is to conduct a longitudinal prospective study of overweight\u002Fobese (OW\u002FOB) pregnant women and their offspring to determine which prenatal exercise mode will have the greatest impact on maternal and infant cardiometabolic health. This information may lead to clinical practice recommendations that improve childhood health. This randomized controlled trial will recruit 284 OW\u002FOB pregnant women randomized to an exercise intervention (aerobic (AE), resistance (RE), or aerobic+resistance exercise (AERE)) or to no exercise; their infants will be measured at 1, 6, and 12 months of age. This design will test our central hypothesis that AERE and RE training during pregnancy will improve maternal and offspring cardiometabolic outcomes to a greater extent than AE alone. This hypothesis will be tested with two specific aims:\n\nAim 1. Determine the influence of different exercise modes during OW\u002FOB pregnancy on infant cardiometabolic health and growth trajectories. Hypothesis: AE, RE, and AERE by OW\u002FOB pregnant women will improve offspring neuromotor and cardiometabolic measures at 1, 6, and 12 months postpartum (e.g. decreased %body fat, BMI z-score, heart rate \\[HR\\], non-HDL, and C-Reactive Protein (CRP); increased insulin sensitivity) compared to infants of OW\u002FOB pregnant women that do not exercise; AERE and RE will have the greatest impact on improving infant measures.\n\nAim 2. Determine the most effective exercise mode in OW\u002FOB pregnancy on improving maternal cardiometabolic health outcomes. Hypothesis: AE, RE, and AERE by OW\u002FOB pregnant women will improve both maternal cardiometabolic health measures (e.g. decreased BMI z-score, non-HDL, % body fat, HR, weight gain) across pregnancy (16-36 weeks' gestation) and overall pregnancy outcomes (e.g. lower incidence of gestational diabetes, pre-eclampsia, hypertension during gestation) compared to OW\u002FOB pregnant women that do not exercise; AERE and RE will have the greatest impact on improving maternal health measures, with the AERE group having the highest compliance.\n\nThe proposed study will be the first to provide an understanding of the influence of maternal exercise modes on the cardiometabolic health and growth trajectories of offspring who are at increased risk due to maternal OW\u002FOB. This work will have a significant impact on reducing the cycle of OB, potentially providing the earliest and most efficacious intervention to decrease or prevent OB in the next generation.",[169,31],[216],"exercise modes, exercise intervention","2026-06-02",{"date":170,"type":36},{"date":220,"type":36},"2021-10-18",{"date":222,"type":23},"2027-08-30",{"name":224,"class":43},"East Carolina University",{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":20,"enrollmentInfo":233,"targetDuration":4,"studyType":24,"phases":235,"briefSummary":236,"conditions":237,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":44},"100638870","phase-3-a-study-of-da-302168s-in-participants-with-overweightobesity-100638870","NCT07629544","A Study of DA-302168S in Participants With Overweight\u002FObesity","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight\u002FObese Participants","PANDA-1","Key Inclusion Criteria:\n\n1. Age 18-75 years (inclusive), both males and females;\n2. BMI requirements at screening: for obese participants, BMI ≥28 kg\u002Fm² with or without comorbidities; or for overweight participants, BMI ≥24.0 kg\u002Fm² and \\\u003C28 kg\u002Fm² with at least one of the following comorbidities: hypertension, prediabetes, dyslipidemia, weight-bearing joint pain (as determined by the investigator, excluding joint pain caused by other diseases), obstructive sleep apnea syndrome, or metabolic dysfunction-associated steatotic liver disease;\n3. Body weight change \\\u003C5% (based on participant self-report, calculated as \\[maximum weight - minimum weight\\] \u002F maximum weight, with the result rounded to one significant digit) during the 3 months prior to screening, while on diet and exercise control (based on participant self-report).\n\nExclusion Criteria:\n\n1. Type 1 diabetes, type 2 diabetes, or other specific types of diabetes (excluding gestational diabetes);\n2. Secondary obesity, history of bariatric surgery;\n3. Presence of gastrointestinal diseases affecting drug absorption, dysphagia;\n4. Personal\u002Ffamily history of medullary thyroid carcinoma, C-cell hyperplasia, or multiple endocrine neoplasia type 2; uncontrolled hyperthyroidism or hypothyroidism without standard stable management; thyroid nodule with TI-RADS grade 4 or above;\n5. History of acute pancreatitis, chronic pancreatitis, or pancreatic injury within 6 months prior to screening (high-risk pancreatic conditions); acute cholecystitis within the past 3 months, or current cholecystitis, cholangitis, cholelithiasis, or other high-risk gallbladder diseases (except for those with prior cholecystectomy and judged eligible by the investigator);\n6. Severe unstable psychiatric disorder, depression, or history of suicide attempt; score ≥15 on the Patient Health Questionnaire-9 (PHQ-9) at screening, or presence of suicidal ideation\u002Fsuicidal behavior indicated by the Columbia-Suicide Severity Rating Scale (C-SSRS);\n7. Any of the following abnormal clinical laboratory results (local laboratory) at screening: anemia (hemoglobin \\\u003C110 g\u002FL for males, \\\u003C100 g\u002FL for females); liver enzymes, bilirubin, amylase, or lipase exceeding the specified multiples of the upper limit of normal; calcitonin ≥50 ng\u002FL (pg\u002FmL); estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin\u002F1.73m²; triglycerides \\>5.65 mmol\u002FL; thyroid-stimulating hormone \\>6 mIU\u002FL or \\\u003C0.4 mIU\u002FL;\n8. Uncontrolled hypertension (systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg);\n9. Abnormal heart rate on resting electrocardiogram, atrioventricular block, prolonged QTcF interval, bundle branch block, or other clinically significant arrhythmias; history of myocardial infarction, unstable angina, severe cardiac insufficiency, coronary intervention\u002Fbypass, or other cardiovascular\u002Fcerebrovascular diseases within 6 months prior to enrollment;\n10. Use of weight-loss drugs or weight-loss herbal medicines, any hypoglycemic agents, antidepressants, antipsychotics, antiepileptics, or lithium salts within 3 months prior to screening; use of systemic glucocorticoids (except for continuous cumulative use \\\u003C7 days); active autoimmune disease requiring systemic glucocorticoid therapy during the study period.",{"count":234,"type":23},840,[190],"This study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study aimed at evaluating the efficacy, safety, and pharmacokinetic (PK) characteristics of DA-302168S tablets in overweight or obese participants in China.",[31],"2026-06-01",{"date":240,"type":36},"2026-06-05",{"date":242,"type":23},"2026-06-27",{"date":244,"type":23},"2027-10-19",{"name":246,"class":247},"Chendu DIAO Pharmaceutical Group CO., LTD.","INDUSTRY",{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":17,"sex":18,"minAge":54,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":24,"phases":259,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":271},"100580813","phase-1-a-phase-12a-study-of-wve-007-in-adults-living-with-overweight-or-obesity-100580813","NCT06842186","A Phase 1\u002F2a Study of WVE-007 in Adults Living With Overweight or Obesity","A Phase 1\u002F2a, Randomized, Double-blind, Placebo-controlled Study of Ascending Doses of WVE-007 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults Living With Overweight or Obesity","INLIGHT","Inclusion Criteria: Part A\n\n* Male and female participants aged 18 to 60 years\n* BMI 28 to 35 kg\u002Fm2 which has been stable (±5%) for the previous 3 to 6 months (based on participant self-report or medical records). For participants considered for enrollment in a cohort expansion, BMI 28 to 40 kg\u002F m2 will be allowed.\n* Healthy, in the opinion of the Investigator, as determined by prestudy medical history, physical examination, and clinical laboratory assessments\n\nInclusion Criteria : Part B\n\n* Male and female participants aged 18 to 60 years\n* BMI 35 to 50 kg\u002Fm2 (inclusive)\n* Thyroid stimulating hormone is within normal range at Screening. May be on supplemental thyroid hormone as managed by their prescribing physician and stable within the last 60 days\n* Have Pre T2D or T2D\n\nExclusion Criteria: Part A\n\n* History or presence of CV disease, including heart failure (New York Heart Association \\[NYHA\\] Class III or IV), myocardial infarction, angina, or clinically significant abnormal laboratory assessments\n* History or presence of thyroid disorders\n* Medical history or diagnosis of causes of liver disease\n* Use of any siRNA agent in the prior 12 months\n* Received an investigational agent within 90 days or 5 half-lives, whichever is longer, before the first dose of study drug or are in follow-up of another clinical study\n\nExclusion Criteria: Part B\n\n* History of significant CV disease in the opinion of the Investigator.\n* Use of prescription medications (ie, anti-obesity or psychiatric medications) within 14 days or 7 half-lives (whichever is longer) before the first dose of study drug, except for allowed antihypertensive medications and statins.\n* Taking \\>2 antihypertensive medications, or antihypertensive medication dose was changed in the 60 days prior to Screening.\n* Taking \\>1 cholesterol-lowering medication, or cholesterol-lowering medication dose was changed in the 60 days prior to Screening.\n* Cohorts 1 and 2 (preT2D) only: use of any GLP-1 receptor agonists or dual incretin agonists within the 4 months prior to Screening.\n* Cohorts 4 and 5 (T2D) only: use of insulin or any medication that directly stimulates pancreatic insulin within the 60 days prior to Screening, including sulfonylureas, meglitinides, GLP-1 receptor agonists, dual incretin agonists, and DPP-4 inhibitors.\n* Use of any siRNA agent in the prior 12 months.\n* Received an investigational agent within 90 days or 5 half-lives, whichever is longer, before the first dose of study drug or are in follow-up of another clinical study.","60 Years",{"count":258,"type":23},296,[260,189],"PHASE1","The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of WVE-007 when administered subcutaneously (SC) . Part A is a single ascending dose study in adults living with overweight and obesity. The Part B of the study is a repeat dose administration in two adult populations: Pre Type 2 diabetes (Pre T2D) and Type 2 Diabetes (T2D) in adults who are affected by obesity.",[31],"2026-05-29",{"date":217,"type":36},{"date":266,"type":36},"2025-01-31",{"date":268,"type":23},"2027-12",{"name":270,"class":247},"Wave Life Sciences USA, Inc.",6,{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":278,"eligibilityCriteria":279,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":256,"enrollmentInfo":280,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":282,"conditions":283,"keywords":287,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":4},"100638273","ai-driven-metabolic-cohort-in-overweightobese-chinese-adults-100638273","NCT07584330","AI-Driven Metabolic Cohort in Overweight\u002FObese Chinese Adults","Chinese Overweight\u002FObese - Diabetes Metabolic Spectrum Cohort: An Artificial Intelligence-Driven Prospective Study","COMET-AI","Inclusion Criteria:\n\n1. Able to understand and voluntarily sign the informed consent form, and willing to comply with all study requirements.\n2. Age between 18 and 60 years (inclusive).\n3. Meets at least one of the following overweight\u002Fobesity criteria: a) BMI ≥ 24 kg\u002Fm²; b) male waist circumference ≥ 90 cm, female waist circumference ≥ 85 cm.\n4. Capable of basic smartphone operation and able to use WeChat or similar communication tools for daily communication.\n\nExclusion Criteria:\n\n1. Diagnosis of type 1 diabetes, latent autoimmune diabetes in adults (LADA), maturity-onset diabetes of the young (MODY), or other specific types of diabetes.\n2. Endocrine or metabolic diseases that may affect body weight, including untreated thyroid disorders (hyperthyroidism: TSH \\\u003C 0.1 mIU\u002FL with FT4 \\> upper normal limit; hypothyroidism: TSH \\> 10 mIU\u002FL), Cushing syndrome, acromegaly, polycystic ovary syndrome, or hypopituitarism.\n3. Severe liver disease (Child-Pugh class B or C).\n4. Renal insufficiency (estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m²).\n5. Severe cardiac dysfunction (New York Heart Association class III or IV).\n6. Major cardiovascular or cerebrovascular event within the past 3 months (acute coronary syndrome, stroke).\n7. Uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg or diastolic ≥ 110 mmHg) or uncontrolled diabetes (HbA1c ≥ 9.0%).\n8. Active malignancy (diagnosed or treated within the last 3 years).\n9. Inflammatory bowel disease or conditions causing malabsorption (Crohn disease, active ulcerative colitis, pancreatitis with steatorrhea).\n10. Neuropsychiatric disorders (anorexia nervosa, bulimia nervosa, schizophrenia, major depression, or bipolar disorder).\n11. Diseases or physical conditions that impair motor function (severe osteoarthritis, Parkinson disease, paralysis, or cardiopulmonary insufficiency).\n12. Long-term use of antipsychotic drugs, systemic glucocorticoids, or other medications judged by the investigator to affect study outcomes.\n13. Pregnancy or planned pregnancy during the study period.\n14. History of or planned organ transplantation.\n15. Inability to operate the AI-based system or comply with follow-up procedures.\n16. Concurrent participation in another interventional clinical trial that may influence the results of this study.\n17. Unwilling or unable to provide informed consent.",{"count":281,"type":23},2800,"The goal of this observational cohort study is to delineate the five-year dynamic trajectories of metabolic phenotypes in Chinese adults with overweight or obesity, with or without type 2 diabetes, focusing on transition rates from metabolically healthy overweight\u002Fobesity to unhealthy overweight\u002Fobesity or to type 2 diabetes, as well as the incidence and progression of diabetic complications and cardiovascular events in those with type 2 diabetes and overweight\u002Fobesity. Researchers will compare three phenotype groups, namely metabolically healthy overweight\u002Fobesity, metabolically unhealthy overweight\u002Fobesity, and type 2 diabetes with overweight\u002Fobesity, to assess differences in metabolic parameter changes, complication rates, and cardiovascular risk. Participants will use a digital health management platform for data upload and lifestyle support, and will complete comprehensive health assessments at baseline, at 2.5 years, and at 5 years, along with annual light follow-ups.",[31,284,285,286],"Diabetes Mellitus, Type 2","Prediabetic State","Metabolic Syndrome",[31,288,286,289,290,291],"Type 2 Diabetes Mellitus","Metabolic Phenotype","Prospective Study","Cohort Study","2026-05-07",{"date":294,"type":36},"2026-05-13",{"date":296,"type":23},"2026-05-01",{"date":298,"type":23},"2032-04-01",{"name":300,"class":43},"Zhujiang Hospital",{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":17,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":311,"conditions":312,"keywords":314,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":44},"100626127","prognostic-value-of-sii-and-siri-in-obesity-related-metabolic-complications-100626127","NCT07431593","Prognostic Value of SII and SIRI in Obesity-Related Metabolic Complications","Clinical Significance and Prognostic Value of Systemic Immune Inflammation Index and Systemic Inflammation Response Index in Obesity and Associated Metabolic Complications","SIMO-PRO","Inclusion Criteria\n\n* Age ≥ 18 years\n* BMI 25.0-29.9 kg\u002Fm² (overweight) or BMI ≥ 30 kg\u002Fm² (obesity)\n* Ability to attend scheduled clinical visits\n* Willingness to provide informed consent\n\nExclusion Criteria\n\n* Pregnancy or breastfeeding\n* Use of immunosuppressive therapy\n* Active infection\n* Inflammatory disease\n* Malignancy\n* Acute illness affecting immune parameters\n* Conditions interfering with study participation (as assessed by the investigator)\n* Known hematologic disorders affecting leukocyte or platelet counts\n* Chronic inflammatory diseases requiring systemic therapy\n* Recent major surgery (within the last 3 months)\n* Any condition that could confound the relationship between SII\u002FSIRI and obesity-driven inflammation, such as immune disorders",{"count":310,"type":23},200,"This observational study aims to evaluate the diagnostic and prognostic value of the systemic immune-inflammatory index (SII) and the systemic inflammation response index (SIRI) in individuals with overweight or obesity. The study will assess their association with obesity status, metabolic complications, lifestyle patterns, dietary indices, and established inflammatory biomarkers. Participants will undergo anthropometric assessment, laboratory testing, dietary evaluation, and follow-up for response to different obesity treatment modalities over 3 years. The study intends to determine whether SII and SIRI can serve as clinically useful predictors of metabolic risk and treatment outcomes of obesity.",[31,313,286],"Inflammation",[315,316,317,318,319],"obesity","overweight","Systemic Immune Inflammatory Index (SII)","Systemic Inflammation Response Index (SIRI)","inflammation","2026-04-30",{"date":292,"type":36},{"date":323,"type":23},"2026-04",{"date":325,"type":23},"2027-12-31",{"name":327,"class":43},"University of Rijeka",{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":17,"sex":18,"minAge":54,"maxAge":256,"enrollmentInfo":336,"targetDuration":4,"studyType":24,"phases":338,"briefSummary":340,"conditions":341,"keywords":342,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":356},"100544589","early-phase-1-abundance-of-a-natural-odour-in-human-cerebrospinal-fluid-after-olfactory-exposure---the-olfo-brain-study-100544589","NCT06370845","ABUNDANCE of A NATURAL ODOUR in HUMAN CEREBROSPINAL FLUID AFTER OLFACTORY EXPOSURE - the OLFO-Brain Study","Abundance of a Natural Odour in Human Cerebrospinal Fluid After Olfactory Exposure - the OLFO-Brain Study","OLFO-Brain","Inclusion Criteria Obese Participants:\n\n* Age 18-60 years\n* Written informed consent\n* Scheduled for routine liquor puncture\n* BMI ≥ 30 kg\u002Fm2\n* No proven diagnose of diabetes\n\nInclusion Criteria Lean Participants:\n\n* Age 18-60 years\n* Written informed consent\n* Scheduled for routine liquor puncture\n* BMI 18-25 kg\u002Fm2\n\nExclusion Criteria:\n\n* Known allergy to the natural odour\n* Acute upper respiratory tract infection, acute or chronic sinusitis\n* Present or past surgical intervention of the nasal cavity, the paranasal sinus, the pituitary or the frontal brain\n* Pregnancy\u002Flactation\n* Any kind of severe chronic disease (e.g. severe heart failure, active cancer disease, severe renal impairment with an estimated glomerular filtration rate \\\u003C30 ml\u002Fmin\u002Fm2)\n* Inability to understand the study procedure and to sign the study consent",{"count":337,"type":23},32,[339],"EARLY_PHASE1","The goal of this clinical trial is to investigate the abundance of a natural odour in human cerebrospinal fluid in obese and lean participants after inhalation thereof. Participants will undergo blood sample collection and inhalation of either a natural odour or placebo through an inhaler in addition to a liquor puncture prescribed in standard of care context.",[31],[343,344,345,346],"natural odour Inhalation","RCT","Placebo Controlled","Cerebrospinal Fluid","2026-04-28",{"date":349,"type":36},"2026-05-04",{"date":351,"type":36},"2026-04-14",{"date":353,"type":23},"2027-10-30",{"name":355,"class":43},"University Hospital, Basel, Switzerland",2,{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":12,"sex":18,"minAge":364,"maxAge":54,"enrollmentInfo":365,"targetDuration":4,"studyType":24,"phases":367,"briefSummary":368,"conditions":369,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":44},"100635934","phase-1-a-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-hrs9531-injection-in-adolescents-with-obesity-100635934","NCT07559136","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity","A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of HRS9531 Injection in Chinese Adolescents With Obesity","Inclusion Criteria:\n\n1. Male or female subjects who are aged ≥12 years and \\\u003C18 years at the time of signing the informed consent;\n2. At screening, the BMI meets the obesity criteria according to \"WS\u002FT586-2018 Screening Criteria for Overweight and Obesity in School-age Children and Adolescents\";\n3. Subjects who have maintained a controlled diet and exercise for at least 12 weeks prior to screening, with no more than a 5% decrease in BMI (as reported by the subject, parent, or legal guardian);\n\nExclusion Criteria:\n\n1. Presence of clinically significant lab results at screening visit;\n2. Uncontrollable hypertension;\n3. Medical history or illness that affects your weight;\n4. History of diabetes;\n5. Acute infection, acute trauma, or medium to large surgery within 1 month prior to screening;\n6. Confirmed or suspected depression, bipolar disorder, suicidal tendencies, schizophrenia, or other serious mental illness;\n7. Use of drugs or treatments that may have caused significant weight gain or loss within the 3 months prior to screening;\n8. Pre-adolescent participants (Tanner phase I);\n9. Patients with blood donation or blood loss ≥400 mL or receiving blood transfusion within 3 months before screening.\n10. Surgery is planned during the tria;\n11. Mentally incapacitated or speech-impaired subjects are unable to fully understand or participate in the test process；\n12. In the investigator's judgment, there are circumstances that affect subject safety or any other conditions that interfere with the evaluation of the test results.","12 Years",{"count":366,"type":23},48,[260],"The aim of this trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS9531 injection compared with placebo in adolescents with obesity",[31],"2026-04-23",{"date":320,"type":36},{"date":373,"type":23},"2026-05",{"date":375,"type":23},"2027-02",{"name":377,"class":247},"Fujian Shengdi Pharmaceutical Co., Ltd.",{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":17,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":387,"conditions":388,"keywords":389,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":401,"leadSponsor":403,"locationsCount":4},"100634606","weight-loss-goals-and-satisfaction-survey-100634606","NCT07541872","Weight Loss Goals and Satisfaction Survey","An Evaluation of 3D Visualization Tools and Their Effect on Weight Loss Goals and Satisfaction","Inclusion Criteria:\n\n* Adults over 18 years of age\n* BMI ≥ 24.5 kg\u002Fm2\n* currently seeking weight loss\n* Willingness to provide informed consent\n* Willingness to answer all questions related to enrollment criteria and provide the necessary information to render a personalized avatar, including sex, age, race\u002Fethnicity, weight, and height.\n\nExclusion Criteria:\n\n• History of body shape-altering procedures (i.e., breast augmentation, bariatric surgery, amputation)",{"count":386,"type":23},250,"The goal of this observational survey pilot study is to learn how 3D visualization tools (i.e., personalized avatars) influence weight loss goals, satisfaction, confidence, and commitment compared to numerical weight outcomes in weight loss-seeking adults.\n\nThe main questions it aims to answer are:\n\n1. What are contemporary weight loss goals (defined as dream, happy, acceptable, and disappointing weight loss outcomes), and how do they compare to goals reported in prior studies?\n2. Does presenting weight loss outcomes using personalized 3D avatars result in different levels of satisfaction compared to presenting equivalent outcomes numerically as body weight?\n3. Do predictive 3D avatars affect participants' confidence and commitment to achieving weight loss differentially than numerical weight loss goals?\n\nResearchers will compare visual (3D avatar-based) weight loss outcomes to numerical (pounds lost) weight loss outcomes to see if visual presentation lowers satisfaction with potential weight loss and alters confidence and commitment.\n\nParticipants will:\n\n* Complete a one-time online survey\n* Provide demographic and self-reported anthropometric information to generate personalized 3D avatars\n* Report weight loss goals and rate satisfaction with potential weight loss outcomes shown numerically and as 3D avatars.\n* Complete questionnaires assessing psychological and behavioral weight-related factors.",[31],[390,391,392,393,394,395,396],"weight loss","health behavior","motivation","three-dimensional imaging","digital health","treatment expectations","health communication","2026-04-13",{"date":399,"type":36},"2026-04-21",{"date":38,"type":23},{"date":402,"type":23},"2026-09",{"name":404,"class":43},"Pennington Biomedical Research Center",{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":409,"acronym":4,"eligibilityCriteria":410,"healthyVolunteers":17,"sex":18,"minAge":54,"maxAge":411,"enrollmentInfo":412,"targetDuration":4,"studyType":24,"phases":413,"briefSummary":414,"conditions":415,"keywords":418,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":430,"locationsCount":44},"100543301","phase-1-human-models-of-selective-insulin-resistance-alpelisib-part-i-100543301","NCT06354088","Human Models of Selective Insulin Resistance: Alpelisib, Part I","Inclusion Criteria:\n\n1. Adults aged 18-70 years\n2. Able to understand written and spoken English and\u002For Spanish\n3. Body mass index of:\n\n   * For Group IS: BMI 18-25 kg\u002Fm2\n   * For Group IR: BMI 30-45 kg\u002Fm2\n4. Evidence of insulin sensitivity or insulin resistance:\n\n   * Insulin sensitive (for Group IS) defined as all of the following: (1) Fasting serum insulin ≤ 10 µIU\u002FmL, (2) Absence of dysglycemia (fasting plasma glucose \\\u003C 100 mg\u002FdL and hemoglobin A1c \\\u003C 5.7%), (3) Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) score \\\u003C 2.5, and (4) Fibrosis-4 (FIB-4) score \\\u003C 1.3\n   * Insulin resistant (for Group IR) defined as fasting serum insulin ≥ 13 µIU\u002FmL plus at least one of the following: (1) Presence of prediabetic state (fasting plasma glucose 100-125 mg\u002FdL and\u002For hemoglobin A1c 5.7-6.4%), and\u002For HOMA-IR ≥ 2.5\n\nExclusion Criteria:\n\n1. Inability to provide informed consent in English or Spanish\n2. Concerns arising at screening visit:\n\n   * Abnormal vital signs: (1) Systolic blood pressure \\\u003C 90 mm Hg or \\> 160 mm Hg and\u002For (2) Diastolic blood pressure \\\u003C 55 mm Hg or \\> 100 mm Hg and\u002For (3) Abnormal resting heart rate \\\u003C 55 bpm (except at PI's discretion) or ≥ 110 bpm\n   * Abnormal screening serum electrolytes judged by the PI to be potentially clinically significant, including liver function abnormalities (either of the following): (1) Transaminases (AST or ALT) \\> 3.0 x the upper limit of normal and\u002For (2) Total bilirubin \\> 1.25 x the upper limit of normal\n   * Laboratory evidence of diabetes mellitus: (1) Hemoglobin A1c ≥ 6.5%, and\u002For (2) Fasting plasma glucose ≥ 126 mg\u002FdL\n3. Reproductive concerns i. Positive qualitative β-hCG (i.e., pregnancy test) in women of childbearing potential ii. Women currently pregnant iii. Women currently breastfeeding\n4. Concerns related to glucose metabolism\n\n   * History of having met any of the American Diabetes Association's definitions of diabetes mellitus (i.e., overt diabetes)\n   * History of gestational diabetes mellitus within the previous 5 years\n   * Use of most antidiabetic medications (other than metformin) within the 90 days prior to screening: thiazolidinediones, sulfonylureas, meglitinides, dipeptidyl peptidase-4 (DPP4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, amylin mimetics, acarbose, insulin iv. Clinical concern for absolute insulin deficiency (e.g., type 1 diabetes, pancreatic disease)\n5. Concerns related to lipid metabolism\n\n   * Known diagnoses of familial hypercholesterolemia, familial combined hyperlipidemia, or familial hyperchylomicronemia in the participant or a first-degree relative\n   * Use of certain lipid-lowering drugs within 14 d prior to screening visit: fibrates (e.g., fenofibrate, gemfibrozil), prescription-strength omega-3 fatty acids (e.g., icosapent ethyl), high-dose niacin (\\>100 mg daily)\n6. Known, documented history, at the time of screening, of any of the following medical conditions:\n\n   * Significant cardiovascular diseases (N.B. uncomplicated hypertension is not exclusionary)\n   * Severe liver disease, including advanced fibrosis (e.g., fibrosis score F3-F4 by vibration-controlled transient elastography) and cirrhosis\n   * Psychiatric diseases causing functional impairment that: (1) Are or have been decompensated within 1 year of screening, and\u002For (2) Require use of anti-dopaminergic antipsychotic drugs associated with significant weight gain\u002Fmetabolic dysfunction (e.g., clozapine, olanzapine)\n   * Venous thromboembolic disease (deep vein thrombosis or pulmonary embolism) or any required use of therapeutic anticoagulation\n   * Bleeding disorders, including due to anticoagulation, or significant anemia (see above)\n   * Active malignancy, or hormonally active benign neoplasm, except allowances for non-melanoma skin cancer and differentiated thyroid cancer (Stage I only)\n7. Clinical concern for increased risk of volume overload, including due to medications and\u002For heart\u002Fliver\u002Fkidney problems, as listed above\n8. Use of oral or parenteral corticosteroids (at greater than prednisone 5 mg daily, or equivalent) for more than 3 days within the previous 30 days; topical and inhaled formulations are permitted\n9. History of certain weight-loss (bariatric) surgery, including:\n\n   * Roux-en-Y gastric bypass\n   * Biliopancreatic diversion\n   * Restrictive procedures (lap band, sleeve gastrectomy) performed within the past 6 months\n10. Clinical concern for alcohol overuse based on chart review and\u002For by recruit's report of more than 14 standard drinks per week for males or more than 7 standard drinks per week for females\n11. Regular use of tobacco, either daily or an average of at least 1 cigarette per day, and\u002For nicotine vaping more than 1 day per week\n12. Clinical concern for use of illicit drugs other than marijuana or lawfully prescribed medications based on recruit's report, chart review, and point-of-care urine drug test at screening\n13. History of or ongoing febrile illness within 30 days of screening\n14. Any other disease or condition or laboratory value that, in the opinion of the investigator, would place the participant at an unacceptable risk and\u002For interfere with the analysis of study data.\n15. Known allergy\u002Fhypersensitivity to any component of the medicinal product formulations (including soy, cow dairy, or gluten), other biologics, venipuncture materials, plastics, adhesive or silicone, or ongoing clinically important allergy\u002Fhypersensitivity as judged by the investigator.\n16. Dietary restrictions (e.g., vegan, kosher, halal) on gelatin present in overencapsulation\n17. Concurrent enrollment in another clinical study of any investigational drug\u002Fbiologic therapy within 6 months prior to screening or within 5 half-lives of an investigational agent or biologic, whichever is longer.\n\n    * Prior participation in other studies led by Dr. Cook (PI) is excluded from this prohibition according to his medical\u002Fscientific judgment.","70 Years",{"count":337,"type":23},[260],"The goal of this clinical trial is to understand how the blood sugar-lowering hormone insulin works in healthy adults versus those who are at risk for type 2 diabetes. The study will use a drug called alpelisib, which interferes with insulin's actions in the body, to answer the study's main question: does the liver continue to respond to insulin's stimulation of fat production even when it loses the ability to stop making glucose (sugar) in response to insulin. Researchers will compare the impact of single doses of both alpelisib and placebo (inert non-drug) in random order (like flipping a coin) in study participants. Participants will be asked to stay twice overnight in the hospital, take single doses of alpelisib and placebo (one or the other on each of the two hospital stays), and receive intravenous (into the vein) infusions of non-radioactive \"tracer\" molecules that allow researchers to measure the production of glucose (sugar) and fats by the liver. Measurements will be done both overnight, while participants are asleep and fasting (not eating or drinking other than water) and while consuming a standardized diet of nutritional beverages during the following day.\n\nThe objective is to evaluate the effect of lowering insulin levels, while maintaining constant mild hyperglycemia, on plasma glucose and lipid levels.",[416,285,31,417],"Insulin Resistance","Non-Alcoholic Fatty Liver Disease",[419,420,417,421,422,423],"Insulin resistance","Hyperinsulinemia","Hepatic steatosis","De novo lipogenesis","Glucose production","2026-04-06",{"date":426,"type":36},"2026-04-09",{"date":428,"type":36},"2024-04-24",{"date":116,"type":23},{"name":431,"class":43},"Columbia University",{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":436,"acronym":437,"eligibilityCriteria":438,"healthyVolunteers":17,"sex":18,"minAge":54,"maxAge":439,"enrollmentInfo":440,"targetDuration":4,"studyType":24,"phases":442,"briefSummary":443,"conditions":444,"keywords":445,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":462,"locationsCount":44},"100407291","testing-the-adipose-expandability-hypothesis-in-vivo-during-overfeeding-100407291","NCT04583514","Testing the Adipose Expandability Hypothesis In Vivo During Overfeeding","EAT 2","Inclusion Criteria:\n\n* Men and pre-menopausal women\n* 18-42 years of age\n* BMI 23-35 kg\u002Fm2 (± 0.5 will be accepted)\n* Are willing to drink deuterium-labeled water (2H2O) for 8 weeks\n* Are willing to be randomized to either a CTL or 30% OF group\n* For women, if not using pharmaceutical (hormonal) contraception (i.e. birth control pills, vaginal ring, injections, or implant), must agree to use either a double barrier method as a form of birth control to prevent pregnancy (i.e. male condom with spermicide, with or without cervical cap or diaphragm); use implants or intrauterine contraceptive devices; have a tubal ligation (surgically sterile); practice abstinence; or be in an established relationship with a vasectomized or same sex partner during the entire duration of the study\n* Must be willing to adhere to all study procedures, including attendance at all study visits\n* If enrolled, agree to maintain the same level of physical activity throughout the duration of the study\n* Must be willing to have blood stored for future research\n\nExclusion Criteria:\n\n* Unstable weight in the last 3 months (± \\~5% weight change)\n* Diagnosis of Type 1 or 2 diabetes or a fasting blood glucose \\> 110 mg\u002FdL\n* Average screening blood pressure \\> 140\u002F90 mmHg\n* Diagnosis of major organ disease (e.g. heart, kidney, lung, thyroid, liver disease) or abnormal liver enzymes that are, in the opinion of the MI, clinically significant and represent a problem for study inclusion.\n* Self-reported positive test for human immunodeficiency virus, hepatitis B or hepatitis C\n* Any current or previous eating disorders\n* Chronic use of systemic glucocorticoids (steroids), systemic adrenergic-stimulating agents, beta-blockers, antipsychotic medications, thiazolidinediones and other medications that may cause clinically significant weight gain or loss)\n* Chronic use of prescription weight loss medications or over the counter weight loss medications which, in the opinion of the MI, will impact the study\n* Chronic use of anti-depressant medications for less than 3 months\n* Chronic smokers or users of tobacco products who cannot abstain for the duration of the inpatient visits\n* Previous bariatric or other surgeries for obesity\n* Had cancer in the last 5 years (some skin cancers acceptable)\n* Pregnancy, breastfeeding, or planned pregnancy for the upcoming 6 months\n* Partial or full hysterectomy\n* PCOS\n* Diagnosed psychotic conditions.","42 Years",{"count":441,"type":23},58,[26],"Adipose, or fat, tissue is a plastic organ that retains the ability to expand and store excess calories during positive energy balance in humans. The capacity of subcutaneous (subQ) adipose tissue to expand and remodel is an important determinant of obesity-related health complications, and impaired expansion of subQ fat tissue is thought to contribute to the risk of diseases such as the Metabolic Syndrome (MetS) and type 2 diabetes mellitus (T2D). The objectives of the study are to evaluate the changes and mechanisms of (subQ) adipose tissue expandability that occur as a result of short-term weight gain and to investigate the effects on cardio-metabolic health outcomes. Findings from this study will provide new insight into the dynamics of adipose expansion and remodeling during changes in energy balance and how this may impact future fat tissue function and metabolic health.",[31,286],[133,446,447,448,449,450,451,452,453,454,455],"Adipose tissue","Subcutaneous abdominal","Subcutaneous femoral","Adipocyte","Adipose turnover","Adipose kinetics","Adipogenesis","Ectopic fat","Insulin sensitivity","Deuterium","2026-04-02",{"date":458,"type":36},"2026-04-08",{"date":460,"type":36},"2020-09-15",{"date":116,"type":23},{"name":404,"class":43},{"id":464,"slug":465,"hasResults":12,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":469,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":53,"minAge":54,"maxAge":471,"enrollmentInfo":472,"targetDuration":4,"studyType":24,"phases":474,"briefSummary":475,"conditions":476,"keywords":479,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":44},"100537832","health-outcomes-in-c-section-infants-with-fecal-microbiota-transplantation-100537832","NCT06282952","Health Outcomes in C-Section Infants With Fecal Microbiota Transplantation","Section-Born Infants and SUccessful Health Outcomes After Fecal Microbiota Transplantation (SISU-FMT)","SISU-FMT","Inclusion Criteria:\n\n* Pregnant women age 18-49 years who are scheduled for elective CS at term, are recruited at 36 weeks of gestation during a visit for the assessment of mode of delivery at Oulu university Hospital, Oulu, Finland.\n\nExclusion Criteria:\n\n* Use of regular immunosuppressive biological medication; inflammatory bowel disease in the mother; immunodeficiency disorder of the mother or any first-degree family member of the unborn baby; known or suspected major fetal congenital abnormality; travel outside Europe, the United States, Canada, Japan, Australia, or New Zealand within the last three months; and antibiotic treatment within three months of delivery (excluding prophylactic cefuroxime - or an alternative in case of allergy - administered prior to the elective cesarean section).\n* Infant exclusion criteria are preterm birth (birth before 37 weeks of gestation), birth weight below 2500 g, admission to neonatal intensive care unit, need for respiratory support or antibiotic treatment of the newborn before discharge. In case of a suspected infection or newborn screening result for severe combined immunodeficiency (SCID) is out of the normal range, of the newborn the randomization code can be opened.","49 Years",{"count":473,"type":23},534,[26],"The goal of this clinical trial is to investigate the differences in microbiota, height and weight between infants born by cesarean section and randomized to receive fecal microbiota transplant after birth. The main questions it aims to answer are:\n\n* Could micobiota transplant be used improve gut microbiota and prevent overweight or obesity.\n* Is the source of colonization a modifiable factor and can it be changed by using an early fecal microbiota transplant.",[477,478,31],"Fecal Microbiota Transplantation","Cesarean Section",[477,478,31],"2026-04-01",{"date":482,"type":36},"2026-04-07",{"date":484,"type":36},"2026-03-31",{"date":486,"type":23},"2036-12-31",{"name":488,"class":43},"Oulu University Hospital",{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":493,"acronym":494,"eligibilityCriteria":495,"healthyVolunteers":17,"sex":18,"minAge":496,"maxAge":497,"enrollmentInfo":498,"targetDuration":4,"studyType":24,"phases":500,"briefSummary":501,"conditions":502,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":356},"100423247","role-of-microvascular-insulin-resistance-and-cardiorespiratory-fitness-diabetes-100423247","NCT04791371","Role of Microvascular Insulin Resistance and Cardiorespiratory Fitness Diabetes","REACH","Inclusion Criteria:\n\n* Sedentary (defined as less than 1 hour per week of physical activity)\n* BMI: 25-40\n* Men and women with and without type 2 diabetes\n\nExclusion Criteria:\n\n* Documented cardiovascular disease\n* Uncontrolled hypertension: disease systolic blood pressure (SBP) \\> 150, diastolic blood pressure (DBP)\\> 110\n* Obstructive pulmonary disease or asthma\n* Peripheral neuropathy\n* Physical impairment that would limit exercise ability\n* Subjects taking beta blockers, calcium channel blockers, insulin, or Thiazolidinediones (TZD)\n* Current or past smoking within the last 1 years\n* Current tobacco use\n* Anemia\n* Control HbA1c \\> 5.7, T2DM HbA1c \\> 9\n* Pregnant, nursing or hormonal therapy (other than contraceptives)\n* Peri or post-menopausal women\n* Type 1 diabetes\n* Hepatic or renal disease.","30 Years","55 Years",{"count":499,"type":23},150,[26],"The goal of this two-site grant proposal is to determine the role of the decreased insulin-mediated muscle perfusion found in type 2 diabetes in contributing to the development of cardiac and skeletal muscle dysfunction and subsequent functional exercise impairment. In addition, it is also our goal to determine whether exercise training attenuates insulin resistance and restores insulin-mediated perfusion to the heart and to skeletal muscle, leading to improved cardiac function and exercise performance.",[503,31],"Type 2 Diabetes","2026-03-19",{"date":506,"type":36},"2026-03-23",{"date":508,"type":36},"2022-06-17",{"date":510,"type":23},"2027-02-15",{"name":512,"class":43},"University of Colorado, Denver",{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":17,"sex":18,"minAge":54,"maxAge":411,"enrollmentInfo":520,"targetDuration":4,"studyType":24,"phases":522,"briefSummary":523,"conditions":524,"keywords":527,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":44},"100558766","phase-1-understanding-the-health-effect-of-a-bioactive-peptide-from-egg-a-pilot-study-100558766","NCT06555393","Understanding the Health Effect of a Bioactive Peptide From Egg: A Pilot Study","A Preliminary Human Study on Bioavailability and Efficacy of Bioactive Peptide IRW in Egg White Hydrolysate","Inclusion Criteria:\n\nHealthy control group:\n\n* Men and women aged between 18 and 70 years living in Edmonton (or Edmonton area\u002Fdriving distance).\n* Normal weight (BMI below 25 kg\u002Fm2 or Asian population below 23 kg\u002Fm2 )\n* Waist circumference below the following ethnic specific cut offs: Canada \u002F USA: \\\u003C102 cm men and \\\u003C88 cm women; Europids, Middle-Eastern, Sub-Saharan African, and Mediterranean: \\\u003C94 cm men and \\\u003C80 cm women; Asians, Japanese, South and Central Americans: \\\u003C90 cm men and \\\u003C80 cm women\n* Fasting glucose \\\u003C5.6 mmol\u002FL\n* HbA1c \\\u003C5.6 %\n* Blood pressure \\\u003C130\u002F85 mmHg\n* Triglycerides \\\u003C1.7 mmol\u002FL\n* HDL-Cholesterol \\>1.03 mmol\u002FL men and \\>1.29 mmol\u002FL women\n* Body weight stable (within 3% fluctuation) for at least 6 months prior to the study\n* Individuals who have never smoke, have smoke less than 100 cigarettes in their life or who are long term quitter (quit smoking a year or more ago)\n\nIndividuals at risk of diabetes\u002Fhaving type 2 diabetes:\n\n* Men and women aged between 18 and 70 years living in Edmonton (or Edmonton area\u002Fdriving distance).\n* Overweight or obesity (BMI above 25 kg\u002Fm2 or Asian population above 23 kg\u002Fm2)\n* Waist circumference at or above the following ethnic specific cut offs: Canada \u002F USA: ≥ 102 cm men and ≥ 88 cm women; Europids, Middle-Eastern, Sub-Saharan African, and Mediterranean: ≥ 94 cm men and ≥ 80 cm women; Asians, Japanese, South and Central Americans: ≥ 90 cm men and ≥ 80 cm women\n* Fasting glucose ≥ 6.0 mmol\u002FL\n* HbA1c ≥ 6.0 %\n* Body weight stable (within 3% fluctuation) for at least 6 months prior to the study\n* Individuals who have never smoke, have smoke less than 100 cigarettes in their life or who are long term quitter (quit smoking a year or more ago)\n\nExclusion Criteria:\n\n* Individuals with a previous history of CVD, renal disorder, monogenic dyslipidemia, with endocrine disorders other than T2D\n* Individuals taking chronic anti-inflammatory drugs (including aspirin, antihistamines, and omega-3 supplements)\n* Pregnant\u002Flactating women\n* Individuals aged above 70 years\n* Smokers (current smokers: daily\u002Foccasional and those who have smoked more than 100 cigarettes in their life)\n* Individuals with specific nutritional restrictions (e.g. vegetarianism excluding eggs from their diet, vegan or with egg allergy) will be excluded\n* Individuals with poorly controlled (HbA1c \\>12.0%) diabetes or taking exogenous insulin will be excluded. Other anti-diabetic and lipid-lowering medications will be documented.",{"count":521,"type":23},28,[260],"Bioactive peptides derived from food proteins show potential for improving human health. One of such promising peptides is namely IRW made from egg white hydrolysate and composed of three peptides. This is a feasibility study to assess the acute effect of IRW in egg white hydrolysate for the management of high sugar and blood pressure.\n\nParticipants at high risk of type 2 diabetes (T2D) or having T2D will undergo 4 consecutive treatments of 1 day each (randomly), during which they will consume a standardized breakfast with a smoothie containing different protein powders. Each treatment will be separated by a minimum of 1-week.\n\nParticipants in the healthy control group will undergo 1 treatment only (one day).",[525,526,31],"High Blood Sugar","High Blood Pressure",[528,529,316,315],"high blood pressure","high blood sugar","2026-03-12",{"date":532,"type":36},"2026-03-13",{"date":534,"type":36},"2026-02-25",{"date":536,"type":23},"2026-10",{"name":538,"class":43},"University of Alberta",{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":17,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":24,"phases":548,"briefSummary":549,"conditions":550,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":356},"100556557","ai-pono-cooking-demonstrations-100556557","NCT06526650","'Ai Pono Cooking Demonstrations","The PILI 'Āina Project","Inclusion Criteria:\n\n* Age 18+ (looking for older adults)\n* Native Hawaiian resident in a participating homestead\n* Overweight or obese (BMI ≥ 25 kg\u002Fm\\^2)\n* Prior diagnosis of type 2 diabetes or pre-diabetes, hypertension, and\u002For dyslipidemia (LDL cholesterol ≥ 130 mg\u002FdL)\n* Capable of 150 minutes of moderate physical activity (e.g., brisk walking) per week\n* Willing and able to participate in all aspects of the individual and household-level intervention\n* Fluent in written and spoken English\n\nExclusion Criteria:\n\n* No children\n* Pregnancy\n* Serious illness such as cancer or chronic pain that may contraindicate full participation",{"count":547,"type":23},1780,[26],"Native Hawaiians' traditional lifestyles and diets ensured the mutual health and well-being of the land and its inhabitants, which stand in stark contrast to the disproportionately high prevalence of diet-related, cardiometabolic diseases they experience today. In this project, the investigators will adapt and test an evidence-based multilevel intervention entitled PILI 'Āina to improve the self-management of prevalent cardiometabolic diseases and reduce risk factors for developing new diet-related illnesses and implement and evaluate the impact and sustainability of community-wide cooking demonstrations. The objectives of this project are to optimize the effectiveness and sustainability of PILI 'Āina, improve diet quality, cardiometabolic markers, promote traditional Native Hawaiian diets, and improve social cohesion.",[503,551,552,31],"Hypertension","Dyslipidemias","2026-03-02",{"date":555,"type":36},"2026-03-04",{"date":557,"type":36},"2025-02-12",{"date":559,"type":23},"2028-08",{"name":561,"class":43},"University of Hawaii",{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":544,"acronym":4,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":568,"targetDuration":4,"studyType":24,"phases":570,"briefSummary":549,"conditions":571,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":572,"startDateStruct":573,"completionDateStruct":574,"leadSponsor":576,"locationsCount":356},"100556528","pili-ina-household-100556528","NCT06526273","PILI 'Āina Household","Inclusion Criteria:\n\n* Age 18+ (looking for older adults)\n* Native Hawaiian resident in a participating homestead\n* Overweight or obese (BMI ≥ 25 kg\u002Fm\\^2)\n* Prior diagnosis of T2D or pre-diabetes, hypertension, and\u002For dyslipidemia (LDL cholesterol ≥ 130 mg\u002FdL)\n* Capable of 150 minutes of moderate physical activity (e.g., brisk walking) per week\n* Willing and able to participate in all aspects of the individual and household-level intervention\n* Fluent in written and spoken English\n\nExclusion Criteria:\n\n* No children\n* Pregnancy\n* Serious illness such as cancer or chronic pain that may contraindicate full participation",{"count":569,"type":23},210,[26],[503,551,552,31],{"date":555,"type":36},{"date":557,"type":36},{"date":575,"type":23},"2029-02-26",{"name":561,"class":43},{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":583,"eligibilityCriteria":584,"healthyVolunteers":17,"sex":585,"minAge":586,"maxAge":81,"enrollmentInfo":587,"targetDuration":4,"studyType":24,"phases":589,"briefSummary":590,"conditions":591,"keywords":592,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":604,"locationsCount":44},"100625314","phase-2-biased-grk-signaling-via-2-adrenergic-receptors-in-human-skeletal-muscle-100625314","NCT07421024","Biased GRK Signaling Via β2-Adrenergic Receptors in Human Skeletal Muscle","Biased G Protein-Coupled Receptor Kinase Signaling Via β2-Adrenergic Receptors and Downstream Activation of Protein Synthesis-Regulating Kinases and Receptor Desensitization in Human Skeletal Muscle","ATR","Inclusion Criteria:\n\n* Healthy men\n* Age 21-45 years\n* BMI 25-35 kg\u002Fm\\^2\n* Body fat percentage 25-40%\n* Lean Mass Index 14-22\n\nExclusion Criteria:\n\n* Regular use of or allergy to β2-agonists\n* Serious adverse reactions to β2-agonists\n* Current smoker\n* Regular use of medication (except OTC allergy or analgesics)\n* Abnormal ECG before or after β2-AR stimulation\n* Hypertension\n* Reduced kidney function (eGFR \\\u003C 90 ml\u002Fmin\u002F1.73m\\^2)\n* Cardiovascular, metabolic, gastrointestinal, renal, or pulmonary disease\n* Psychiatric or neurological disorders affecting compliance\u002Fsafety reporting\n* Cancer history within the last 5 years\n* Substance abuse or alcohol intake \\>14 units\u002Fweek","MALE","21 Years",{"count":588,"type":23},10,[189],"This longitudinal mechanistic physiological study examines biased β2-adrenergic receptor (β2-AR) signaling in human skeletal muscle, with emphasis on G protein-coupled receptor kinase (GRK)-mediated pathways. Participants will receive daily oral dosing of the GRK-selective long-acting β2-agonist ATR-258 for 8 weeks. Muscle biopsies and physiological measurements will quantify GRK-, cAMP\u002FPKA-, and β-arrestin-related signaling, fiber-type specificity, and potential receptor desensitization with repeated stimulation.",[31],[593,594,595,596,597],"beta2","muscle","atr-258","adrenergic","biased signaling","2026-02-16",{"date":600,"type":36},"2026-02-19",{"date":602,"type":23},"2026-02-20",{"date":116,"type":23},{"name":605,"class":43},"Morten Hostrup, PhD",{"id":607,"slug":608,"hasResults":12,"nctId":609,"briefTitle":610,"officialTitle":611,"acronym":612,"eligibilityCriteria":613,"healthyVolunteers":17,"sex":18,"minAge":54,"maxAge":411,"enrollmentInfo":614,"targetDuration":4,"studyType":24,"phases":616,"briefSummary":617,"conditions":618,"keywords":620,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":625,"startDateStruct":626,"completionDateStruct":628,"leadSponsor":630,"locationsCount":44},"100605662","effect-of-a-postbiotic-supplementation-in-overweight-and-obese-subjects-a-randomized-controlled-trial-parabiotics-2-100605662","NCT07165431","Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2).","Clinical Evaluation of a Postbiotic Supplement in Overweight and Obese Subjects: A Randomized Controlled Trial.","PARABIOTICS-2","Inclusion Criteria:\n\n* Male and female participants aged 18 to 70 years.\n* Volunteers with overweight or obesity (BMI: ≥ 27-39.9 kg\u002Fm²) and a body fat percentage of ≥ 30% for women and ≥ 20% for men.\n* Stable body weight (±5%) for at least the three months prior to study initiation.\n* Normal physical examination and vital signs, or clinically non-relevant findings for the purposes of the study (i.e., not related to metabolic health).\n* Subjects must be able to understand and willing to sign the informed consent form, and comply with all study procedures and requirements.\n* Continued pharmacological\u002Fhormonal treatment will be permitted provided it does not affect the study parameters and that the dosage has remained stable at least the previous three months to the start of the intervention. Treatment with insulin or any drug with a hypoglycemic effect will be excluded\n* Willingness to undergo all study procedures (including the daily consumption of a 1 g gummy during the intervention).\n* Time and geographic availability to attend the two on-site clinical evaluation sessions at the scheduled times (including a 3-hour session during visit 2).\n\nExclusion Criteria:\n\n* Volunteers undergoing pharmacological treatment will be excluded if the treatment has not been stable for at least 3 months prior to study initiation. Excluded treatments include:\n* Those that alter gastrointestinal function.\n* Chronic use of stomach protectors.\n* Any hypoglycemic drugs or insulin.\n* Subjects with significant functional or structural abnormalities of the digestive system, such as malformations, angiodysplasias, active peptic ulcers, chronic inflammatory or malabsorption diseases, hiatal hernia, chronic reflux, etc.\n* Subjects who have undergone surgical interventions resulting in permanent sequelae in the digestive tract (e.g., gastroduodenostomy) or bariatric surgery.\n* Subjects with chronic metabolic diseases or obesity-related conditions, or systemic intestinal, hepatic, or renal diseases, including type 1 or 2 diabetes, severe dyslipidemia, uncontrolled thyroid disorders, cirrhosis, inflammatory bowel disease, untreated anemia, etc. (Non-alcoholic fatty liver disease will not be an exclusion criterion).\n* Exceeding the alcohol consumption limit established for each sex (more than 14 units per week for women and 20 units per week for men).\n* Pregnant or breastfeeding women, or those planning to become pregnant.\n* Use of nutritional supplements (such as weight loss supplements, newly initiated fiber supplements, probiotics, postbiotics, etc.) containing compounds that may affect study outcomes, unless the participant agrees to discontinue them during the 12-week intervention period and a minimum 15-day washout period prior to baseline measurements is ensured.\n* Blood donation within 14 days prior to the baseline visit.\n* Subjects with any type of cancer or undergoing cancer treatment, or for whom less than 5 years have passed since remission.\n* Subjects allergic to any component of the study product or to any other food that could interfere with or hinder study compliance.\n* Subjects presenting any type of cognitive and\u002For psychiatric impairment.\n* Subjects anticipated to have poor compliance or who, in the investigator's opinion, may have difficulty adhering to study procedures.\n* Subjects currently undergoing treatment for weight loss or body composition modification.\n* Subjects who are taking or have taken antibiotics within 60 days prior to the baseline visit.",{"count":615,"type":23},114,[26],"The principal objective of this project is to evaluate the effect of a postbiotic supplement (inactivated microorganism) on body composition and other physiological and metabolic parameters related to excess body weight in overweight or obese adult men and women, as well as to determine changes in the gut microbiota associated with these outcomes.\n\nSpecific objectives are focus on evaluate the effect of the intervention on the following parameters:\n\n* Changes in body weight and composition.\n* Changes in glucose tolerance.\n* Changes in gut microbiota (metagenomics).\n* Changes in urinary and serum metabolites.\n* Changes in routine biochemical variables related to carbohydrate and lipid metabolism, as well as liver parameters.\n* Changes in specific markers involved in obesity pathology, such as insulin, leptin, adiponectin, and cytokines MCP-1, TNF, CRP, and others.\n* Adherence to the nutritional recommendations and the gummy containing postbiotic formula.\n* Changes in the level of physical activity.\n\nTarget sample size is 114 subjects, including a 10% of drop out.\n\nParticipants will be allocated in two groups for 12 weeks:\n\n* Experimental group (n=57): nutritional recommendations + postbiotic supplement\u002Fgummy.\n* Placebo group (n=57): nutritional recommendations + placebo supplement\u002Fgummy.\n\nParticipants will visit the nutritional intervention unit at weeks 1 and 12. A follow-up phone call will be conducted at week 6.",[29,619,31],"Weight Loss",[621,134,622,623,624],"Postbiotic","Nutritional advice","Microbiota","Glucose tolerance",{"date":600,"type":36},{"date":627,"type":36},"2025-12-01",{"date":629,"type":23},"2026-06-30",{"name":631,"class":43},"Clinica Universidad de Navarra, Universidad de Navarra",{"id":633,"slug":634,"hasResults":12,"nctId":635,"briefTitle":636,"officialTitle":637,"acronym":4,"eligibilityCriteria":638,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":639,"targetDuration":4,"studyType":24,"phases":640,"briefSummary":641,"conditions":642,"keywords":646,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":651,"lastUpdatePostDateStruct":652,"startDateStruct":654,"completionDateStruct":656,"leadSponsor":658,"locationsCount":44},"100537392","nutrition-care-in-patients-living-with-chronic-pain-100537392","NCT06277232","Nutrition Care in Patients Living With Chronic Pain","Developing Nutrition Care Integrated Into Pain Rehabilitation: a Feasibility and Non-Randomized, Controlled Quasi-Experimental Study","Inclusion Criteria:\n\n* Self reported Body Mass Index (BMI)\\>=25;\n* Written consent to participate and attend to the pain rehabilitation program due to disabling chronic pain (on sick leave or experiencing major interference in daily life due to chronic pain)\n* Agreement not to participate in other parallel treatments for weight reduction\n* Not currently using medications of weight reduction\n* Available to get access to internet via own mobile\u002Fcellphone.\n\nExclusion Criteria:\n\n* Health conditions such as pregnancy, active metabolic disease, rheumatoid arthritis, and serious psychiatric disease (investigator's judgement, eg, psychosis or suicidal ideation);\n* Coagulation disorders with predisposition to bleeding, medication with anticoagulants (low- dose aspirin is permitted);\n* hypersensitivity to anaesthetic\n* Difficulties in understanding the Swedish language.",{"count":310,"type":23},[26],"The investigators' purpose is to develop and test the feasibility, usability, and satisfaction of the Diet4painrelief app as a platform for implementing nutrition care in a specialist pain rehabilitation clinic. The Diet4painrelief will consist of two components: a) a screening tool for nutrition status b) an individually tailored behavior change program aiming to improve the dietary habits and behaviors of patients living with chronic pain.\n\nPart I: Included 20 patients with complex chronic pain to examine the feasibility and outcomes of evidence-based Interdisciplinary Pain Rehabilitation Program (IPRP) integrated with nutrition care. The Diet4painrelief includes a screening tool to assess basic nutritional status as well as their intake of key unhealthy and healthy foods and drinks (through three 24hour-dietary recordings or food diary). Thereafter, the patients receive a personalized behavior change program for dietary optimization. The investigators will design and adapt 6 modules in the digital platform (Diet4painrelief app) based on the International Association for the Study of Pain (IASP) recommendations (6 aspects about 'nutrition and pain') and Sweden's food culture. Clinical outcomes using patient-reported data on socio-demographics, pain aspects, psychometric data, physical disability, and quality of life will be measured at three occasions: first appointment (Pre-IPRP), immediately after completing the rehabilitation program (Post-IPRP), and at a 12-month follow-up (FU-IPRP). Blood samples will be taken to identify biomarkers at the same occasions that provide objective information on metabolic and nutritional abnormalities and further to evaluate the effect of the dietary intervention on changing of pain rehabilitation outcomes.\n\nPart II: Included 192 patients with complex chronic pain. Half of the participants receive IPRP and nutrition care (described above) and the other half receive standard IPRP.",[643,31,644,645],"Nutrition Poor","Mobile Phone Use","Pain, Chronic",[647,648,649,650],"Chronic pain","Nutrition care","Pain rehabilitation","eHealth","2026-02-13",{"date":653,"type":36},"2026-02-18",{"date":655,"type":36},"2024-08-01",{"date":657,"type":23},"2028-12-31",{"name":659,"class":660},"Linkoeping University","OTHER_GOV"]